Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 24, 2025
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
View original at finance.yahoo.comLilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium Updated results from the Phase 3 EMBER-3 trial for Inluriyo™ (imlunestrant) alone and in combination with Verzenio® (abemaciclib) in ER+, HER2– metastatic breast…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
At SABCS 2025, Eli Lilly is showcasing new data across their portfolio addressing the three most important biologic targets in HR+ breast cancer: CDK4/6, the estrogen receptor, and PI3K, reflecting continued momentum and commitment to translating biologic conviction into meaningful progress
80% confidencePIK3CA mutations are present in approximately 40% of HR+/HER2- breast cancers
80% confidenceVerzenio has been authorized in more than 90 countries
80% confidenceESR1 mutations are a key driver in ER+ breast cancer resistance
80% confidenceHR+, HER2- breast cancer is the most common form of breast cancer
80% confidenceEli Lilly has nearly 150 years of history pioneering discoveries
80% confidence